Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Company to launch product after the expiry of semaglutide patent in India
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
Subscribe To Our Newsletter & Stay Updated